Notably, serum CCL27 levels show significant changes from before to after treatment in CTCL patients, suggesting that CCL27 could serve as a potential biomarker for the dynamic monitoring of disease progression [54]. Here, CCL27 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.